Get the Stockscreener App
6.53
6.71%
-0.47
After Hours:
6.56
0.03
+0.46%
Pulmatrix Inc stock is traded at $6.53, with a volume of 15,696.
It is down -6.71% in the last 24 hours and down -24.90% over the past month.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
See More
Previous Close:
$7.00
Open:
$6.9118
24h Volume:
15,696
Relative Volume:
0.84
Market Cap:
$30.86M
Revenue:
$11.68M
Net Income/Loss:
$-8.85M
P/E Ratio:
-2.7095
EPS:
-2.41
Net Cash Flow:
$-14.61M
1W Performance:
-6.04%
1M Performance:
-24.90%
6M Performance:
-9.31%
1Y Performance:
+198.17%
1-Day Range:
$6.52
$6.9118
1-Week Range:
$6.51
$7.195
52-Week Range:
$1.78
$10.40
Pulmatrix Inc Stock (PULM) Company Profile
Name
Pulmatrix Inc
Sector
Industry
Phone
(888) 355-4440
Address
945 CONCORD STREET, FRAMINGHAM, MA
Compare PULM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PULM
Pulmatrix Inc
|
6.53 | 30.86M | 11.68M | -8.85M | -14.61M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Pulmatrix Inc Stock (PULM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-18 | Initiated | H.C. Wainwright | Buy |
Pulmatrix Inc Stock (PULM) Latest News
Learn to Evaluate (PULM) using the Charts - news.stocktradersdaily.com
Long Term Trading Analysis for (PULM) - news.stocktradersdaily.com
Financial Comparison: Pulmatrix (NASDAQ:PULM) & Acelyrin (NASDAQ:SLRN) - Defense World
Pulmatrix (NASDAQ:PULM) Now Covered by StockNews.com - Defense World
(PULM) Trading Advice - news.stocktradersdaily.com
Pulmatrix set for merger with Cullgen, seeks asset divestment By Investing.com - Investing.com South Africa
Enliven stops work on solid tumor drug; Pulmatrix to divest assets - Endpoints News
Pulmatrix Announces Divestment Plan for Assets - citybiz
Pulmatrix Announces First Quarter 2025 Financial Results and Div - GuruFocus
Pulmatrix, Inc. SEC 10-Q Report - TradingView
Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets | PULM Stock News - GuruFocus
Pulmatrix set for merger with Cullgen, seeks asset divestment - Investing.com
Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets - WV News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDUS, COOP, ICAD, PULM on Behalf of Shareholders - The Malaysian Reserve
2025-05-13 | SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDUS, COOP, ICAD, PULM on Behalf of Shareholders | NDAQ:ICAD | Press Release - Stockhouse
PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc.PULM - marketscreener.com
(PULM) Proactive Strategies - news.stocktradersdaily.com
Geode Capital Management LLC Boosts Holdings in Pulmatrix, Inc. (NASDAQ:PULM) - Defense World
Pulmatrix, Inc. (NASDAQ:PULM) Holdings Cut by Renaissance Technologies LLC - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
(PULM) Investment Analysis - news.stocktradersdaily.com
Pulmatrix appoints CBIZ as new auditor after Marcum resignation By Investing.com - Investing.com India
Pulmatrix appoints CBIZ as new auditor after Marcum resignation - Investing.com
Pulmatrix Will Discuss Progress At The Aegis Growth Conference On September 21, 2016 - BioSpace
Aspergillosis Market on Track for Major Expansion by 2034, According to DelveInsight | F2G, Pulmatrix, TFF Pharmaceuticals, Scynexis, Pulmocide - The Globe and Mail
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders - ACCESS Newswire
Pulmatrix : Reports 2018 Financial Results; Provides 2019 Outlook on Pulmonary Disease Pipeline - MarketScreener
Pulmatrix Reports 2024 Financials and Merger Plans - TipRanks
Pulmatrix Inc. (PULM) reports earnings - Quartz
Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets - Nasdaq
Pulmatrix (NASDAQ:PULM) Stock Price Crosses Above Fifty Day Moving Average – What’s Next? - Defense World
(PULM) Trading Report - Stock Traders Daily
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TGI, PULM, CCNE, TURN on Behalf of Shareholders - The Malaysian Reserve
2025-02-25 | SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TGI, PULM, CCNE, TURN on Behalf of Shareholders | NDAQ:CCNE | Press Release - Stockhouse
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pulmatrix, Inc. (PULM) - TradingView
PULM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pulmatrix, Inc. Is Fair to Shareholders - Business Wire
PULM stock soars to 52-week high, touches $8.5 amid robust gains - Investing.com India
PULM stock soars to 52-week high, touches $8.5 amid robust gains By Investing.com - Investing.com South Africa
Pulmatrix revises bylaws, changes voting standards - MSN
Pulmatrix revises bylaws, changes voting standards By Investing.com - Investing.com Nigeria
Pulmatrix's Unique Inhaled Drug Candidate Has "Blockbuster" Potential, Says CFO Bill Duke - ACCESS Newswire
Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain - The Manila Times
SEC Form 425 filed by Pulmatrix Inc. - Quantisnow
Cullgen Begins Phase 1 Dosing of its Potential - GlobeNewswire
Aspergillosis Market Expected to rise, 2034 | Regeneron, Pulmocide, Astellas Pharma, Cipla, Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, I - The Globe and Mail
Pulmatrix (NASDAQ:PULM) Coverage Initiated by Analysts at StockNews.com - Defense World
Pulmatrix (NASDAQ:PULM) Earns Hold Rating from Analysts at StockNews.com - Defense World
Pulmatrix Inc Stock (PULM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.68%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):